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words. Of these, 32 studies met the inclusion criteria. Studies indicate that pancreatic 
cancer has an extremely poor prognosis: for all stages combined, the 1- and 5-year 
relative survival rates are 25% and 6%, respectively. Pancreatic cancer is the fourth 
most common cause of cancer-related deaths in the United States and the eighth 
worldwide. More than 50% of patients come to clinical attention with metastatic 
disease, and an additional 30%–40% present with locally advanced tumors. Current 
treatments include surgery and palliative chemotherapy such as gemicitabine and 
gemcitabine/erlotinib combination. Recently nab-paxclitacel was approved based on 
a 1.8 month improvement in the overall survival. ConClusions: This systematic 
review shows that patients with pancreatic cancer have a very low survival rate. There 
is an urgent need for new treatments for these patients.
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objeCtives: This study evaluated the effect of metformin use on survival in 
pancreatic cancer patients with curative resection and type 2 diabetes mellitus 
(T2DM). Methods: A total of 28,862 were initially identified from Korea Center 
Cancer Registry (KCCR) who had diagnostic code for pancreatic carcinoma between 
1 January 2005 and 31 December 2011. Among them, those with curative resec-
tion or T2DM and aged over 40 years were included. Subjects were classified as 
metformin user group if they were prescribed metformin around the time of diag-
nosis for pancreatic cancer. Medication possession ratio (MPR) of more than 80% 
was considered as acceptable adherence. Survival from pancreatic carcinoma was 
identified from the linkage of National Population Registry of the Korea National 
Statistical Office with KCCR through December 31, 2013. Several sensitivity analyses 
were performed to examine the effect of immortal time bias, and confounding vari-
ables. Results: The study included 764 subjects with T2D and pancreatic cancer 
with curative resection, 530 of which were exposed to metformin. In multivariable 
analysis, the adjusted risk for pancreatic cancer specific mortality of metformin 
user was significantly lower than that of metformin non-user (hazard ratio, 0.73; 
95% CI, 0.61 to 0.87; P < 0.001). The adjusted risk for mortality was also significantly 
lower in MPR of more than 80% compared with that of MPR of less than 80% (HR, 
0.60, 95% CI: 0.47-0.76, p-value< 0.001). In addition, similar results were found from 
a serial of seneitivity analysis. ConClusions: Metformin use in diabetic patients 
with pancreatic cancer is associated with improved survival. This may provide a 
rationale for further prospective study of the use of metformin as an adjunct to the 
standard of care in the treatment of pancreatic cancer.
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objeCtives: Statins are frequently prescribed drugs worldwide, used for the 
management and prevention of coronary artery diseases. In contrast to early 
concerns over carcinogenicity of statins, recent evidences suggest that statins 
may have chemo-preventive potential against variety of cancers. We performed a 
detailed meta-analysis of observation studies to quantify the association between 
statins and risk of cancers. Methods: A comprehensive search was performed in 
EMBASE®/Cochrane/Pubmed to retrieve studies investigating association of statins 
and hematological and non-hematological cancers (prostate, breast, lung, and colo-
rectal). The studies were screened and abstracted by two independent reviewers. 
The studies were assessed for heterogeneity and pooled relative risks and 95% CIs 
were calculated using fixed effect and random effect models. Results: Of the 
4500 retrieved articles, 53 observational studies (27 case control and 26 cohort) 
contributed to analysis. The use of statins had modest chemo-protective potential 
against non-hematological cancers (prostate, breast, lung, and colorectal taken alto-
gether). However, the association did not reach statistical significance (RR= 0.93; 
95% CI, 0.87 to 1.0, p= 0.09). There was no significant association between statins 
use and risk of prostate (RR= 0.93; 95% CI, 0.79 to 1.09, p= 0.16), breast (RR= 0.97; 95% 
CI, 0.91 to 1.03, p= 0.3), lung (RR= 0.90; 95% CI, 0.75 to 1.08, p= 0.25), and colorectal 
cancer (RR= 0.94; 95% CI, 0.88 to 1.0, p= 0.06). In contrast, statins use was associated 
with significant reduction in risk of hematological malignancies (RR= 0.82; 95% CI, 
0.67 to 0.99, p= 0.04). Following the statins use, risk of non-hodgkin’s lymphoma 
(RR= 0.69; 95% CI, 0.49 to 0.96, p= 0.03) was reduced whereas no association was 
observed with lymphoma (RR= 0.99; 95% CI, 0.37 to 2.69, p= 0.99). ConClusions: 
Our meta-analysis results demonstrated that statins were associated with a mod-
est reduction in risk of non-hematological cancers, when taken for management 
of hypercholesterolemia. On the contrary, statins demonstrated chemo-protective 
potential against risk of hematological malignancies.
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objeCtives: Trials of new oncology treatments often allow patients to crossover 
from control to experimental treatment either at disease progression or a specific 
time point. If crossover occurs after progression, progression free survival is largely 
unaffected; however overall survival (OS) is confounded in the control arm. Patients 
switching treatments often have different prognoses, resulting in a biased estimated 
OS difference. Advanced statistical methods to adjust for crossover include Rank 
Preserving Structural Failure Time (RPSFT) models, Inverse Probability of Censoring 
[IQR: $13,220-38,966]). Adjusting for patient and facility characteristics, total 
charges for lung ($ 2396, p= 0.03), colorectal ($10,844, p< 0.0001), and pancreatic 
cancers ($ 7504, p< 0.0001) were significantly higher than liver cancers. Significant 
predictors of LOS included race/ethnicity (compared to whites, 15% longer for 
blacks (IRR= 1.15, 95% CI: 1.13-1.17 ) and 4% longer for Hispanics (IRR= 1.04, 95% 
CI: 1.02-1.06) and hospital location (compared to rural hospitals, 12% longer for 
non-teaching urban (IRR= 1.12, 95% CI: 1.10-1.14) and 15% longer for teaching urban 
(IRR= 1.15, 95% CI: 1.13-1.17). ConClusions: We found significant differences in 
proportion of hospitalizations, LOS, and charges between cancer types, moderated 
by patient and facility characteristics. Of the cancer sites considered, liver cancers 
had the lowest incidence of hospitalization, shortest LOS, and lowest total charges.
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objeCtives: To examine the change in renal function among patients with bone 
metastases (BM) from solid tumors (ST) Methods: A retrospective cohort study 
was conducted using OSCER (Oncology Services Comprehensive Electronic Records) 
database, containing electronic medical records from > 50 outpatient oncology/
hematology practice groups in the US. The study sample included adults (age > = 
18 years) diagnosed with a single ST and BM between 01/01/2012 through 09/30/2013. 
Changes in renal function from baseline (6 months prior to the BM diagnosis) over 
the follow-up period were assessed. The outcomes of interest include clinically-
meaningful increase in serum creatinine (SeCr) [defined as 0.5 mg/dL increase 
in patients with normal baseline levels (< 1.4 mg/dL), and 1.0 mg/dL increase in 
those with elevated baseline levels (≥ 1.4 mg/dL)], estimated glomerular filtration 
rate (eGFR), and chronic kidney disease (CKD) stage (1: eGFR> 90 to 5: eGFR< 15). 
Descriptive analysis was conducted to examine baseline patient characteristics 
and change in renal function. Results: A total of 6,380 patients met the eligibility 
criteria; majority of them were female (52%), Caucasian (70%), with mean age of 67 
years (Standard Deviation [SD]: 12), mean SeCr of 1.0 (SD: 0.5), and mean eGFR of 77 
(SD: 23) at baseline. During a median follow-up of 191 days after BM diagnosis, an 
average 11-point (SD: 17) reduction (relative reduction: 13%) in eGFR from baseline 
was observed. Clinically-meaningful increases in SeCr were observed in 10.8% of 
the patients overall; among 7.2% patients from elevated (n= 706) and 11.3% from 
normal (n= 5,674) baseline SeCr levels. Increases in CKD stage from baseline levels 
were observed in 36% of the patients. ConClusions: Worsened renal function was 
observed among patients with ST and BM. Given the use of bone targeting agents 
in this patient population, future analysis is needed to understand the impact of 
those agents, such as zoledronic acid, on renal function.
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objeCtives: Explore the epidemiology and treatment of soft tissue sarcoma (STS) 
in EU5. Methods: Epidemiology of STS was derived from the Kantar Health (KH) 
CancerMPact database, sources for which include country specific cancer regis-
tries, published scientific studies and proprietary physician surveys conducted 
in March 2015 comprising 76 doctors seeing an average of 3,210 STS patients per 
month. Country specific age and gender incidence rates were applied to country 
population data to determine number of newly diagnosed STS patients. Annual 
non-metastatic and metastatic progression rates and annual non-metastatic and 
metastatic survival rates are used to calculate total number of surviving patients 
up to 10 years after diagnosis. Treatment data was determined from the physi-
cian surveys and was country specific. Results: Incidence of STS ranged from 
3.1 – 4.1 per 100K . Among all incident STS patients, 74% were non metastatic and 
16% were metastatic. Surgery/Drug/Radiation rates were, respectively, 43%/37%/19% 
in France, 52%/42%/22% in Germany, 49%/31%/27% in Italy, 41%/34%/29% in Spain 
and 45%/28%/27% in the UK. Among metastatic patients, 41% to 44% received a 
first line drug. There was wide variation in the % of first line that received second 
line (range 35% - 58%) and second line who received third (17% - 30%). Among 
first line drug treated doxorubicin plus ifosfamide was the preferred regimen in 
France, Germany and Spain whereas doxorubicin monotherapy was preferred in UK. 
Trabectedin and pazopanib were used relatively frequently as second or third line 
treatments. ConClusions: This study confirms the rarity of soft tissue sarcoma in 
EU5. Doxorubicin plus ifosfamide is the most commonly used treatment in first line 
across EU5, trabectedin and pazopanib tend to be the most utilized treatments in 
second and third line. Variance to the trend is apparent in France and Spain second 
line and in France and UK third line.
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objeCtives: Pancreatic cancer is considered one of the toughest cancers to treat, with 
extremely poor prognosis. The objective of this research was to conduct a systematic 
review of epidemiology and the burden of pancreatic cancer. Methods: A systematic 
literature search for epidemiology and the burden of disease studies was undertaken 
for the databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was 
collected for the study type, methods, country and key findings. Extracted study data 
included pancreatic cancer incidence, complications, mortality, available treatment 
options, as well as healthcare resource utilization and medical costs associated with 
pancreatic cancer. Critical analyses of study quality and data gaps were analyzed at 
the country level. Results: A total of 328 studies were identified based on the key-
